Latest research on Olmesartan medoxomil

Olmesartan is an antihypertensive agent, which belongs to the class of medications called angiotensin II receptor blockers. It is indicated for the treatment of high blood pressure and is marketed under the name Olmetec®. The FDA label includes a black-box warning of injury and death to the fetus, so women of child-bearing age need to be warned and take the necessary precautions. Olmesartan is also contraindicated in diabetes mellitus patients taking aliskiren.

Olmesartan medoxomil side effects

For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Olmesartan medoxomil may be increased to 40 mg. [source, 2016]
Above all, however, this study was characterized by a different level of significance compared with other studies [24,38,39] given that we demonstrated a positive correlation between the decrease in Hb level and the reduction in albuminuria regarding ARB treatment (especially, 40 mg/day Olmesartan medoxomil), regardless of EPO level, BP, and eGFR. [source, 2015]
In the REZALT study (Efficacy and tolerability of Olmesartan medoxomil and azelnidipine combination therapy compared with monotherapy with each agent in Japanese patients with essential hypertension; Japan Pharmaceutical Information Center registration number, JapicCTI-060286), the combination treatment with olmesartan and azelnidipine resulted in a greater decrease in ambulatory BP than with the corresponding monotherapies [28, 29]. [source, 2015]
There is no relationship between the dose and the occurrence of side effects of Olmesartan medoxomil. [source, 2014]
The occurrence of AEs may not be increased by the increase in olmesartan exposure because there is no relationship between the dose and the occurrence of side effects with Olmesartan medoxomil. [source, 2014]
Is there any additive or increased effect on AEs when Olmesartan medoxomil and Probenecid are administered together? [source, 2014]
The combined treatment of Olmesartan medoxomil and Probenecid may increase the occurrence of genitourinary side effects. [source, 2014]
Other examples of compounds that had their transdermal delivery increased by the use of microemulsions include prodrugs of Nicotinic Acid [102], Lidocaine [67], Estradiol [57], tetramethylpyrazine [103], sodium Diclofenac [48], Buspirone hydrochloride [104], Tolterodine tartrate [105], Huperzine A [106], Meloxicam [107], Diclofenac epolamine [108], triptolide [32], vinpocetine [59] and Olmesartan medoxomil [109]. [source, 2014]
Thus, improving solubility and dissolution rate of Olmesartan medoxomil can increase clinical efficacy or reduce the oral dosage required to achieve the same effect. [source, 2013]
It was concluded that SMEDDS formulations containing Olmesartan medoxomil significantly increase in the dissolution rate and in vitro diffusion rate compared to plain OLM suspension. [source, 2013]